{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103527","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.632064+00:00","generated_at":"2026-05-17T18:58:39.800054+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"EyePoint Q2 net loss $59.4M; completes Phase 3 enrollment for DURAVYU in wet AMD","bullets":["Net revenue $5.3M, down from $9.5M YoY; net loss $59.4M ($0.85/share) vs. $30.8M ($0.58/share) in Q2 2024.","Total operating expenses $67.6M, up from $44.0M, driven by DURAVYU Phase 3 trial costs.","Cash, equivalents and marketable securities $256M as of June 30, 2025; cash runway into 2027.","Completed enrollment in both Phase 3 wet AMD trials (LUGANO and LUCIA) with over 800 patients; topline LUGANO data mid-2026.","Initiated DURAVYU registration batches at Northbridge, MA commercial manufacturing facility."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103527","json":"https://secwatch.observer/filing/0000950170-25-103527.json","markdown":"https://secwatch.observer/filing/0000950170-25-103527.md","text":"https://secwatch.observer/filing/0000950170-25-103527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025103527/0000950170-25-103527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025103527/eypt-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:58:39.800054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}